Product Description
Mechanisms of Action: AT2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Peripheral Nervous System Diseases|Neuralgia, Postherpetic|Pain Unspecified|Neuralgia|Neuropathic Pain|Chemotherapy-induced Peripheral Neuropathy
Phase 1: Neuralgia, Postherpetic|Neuropathic Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12611001185954 |
ACTRN12611001185954 | N/A |
Withdrawn |
Neuropathic Pain |
None |
2026-02-15 |
Treatments |
|
ACTRN12615000074594 |
ACTRN12615000074594 | P1 |
Completed |
Neuropathic Pain |
2015-02-23 |
2026-02-15 |
Treatments |
|
ACTRN12614000802606 |
ACTRN12614000802606 | P1 |
Completed |
Neuropathic Pain |
2014-10-09 |
2024-08-29 |
Treatments |
|
ACTRN12610000961044 |
ACTRN12610000961044 | P1 |
Completed |
Neuralgia, Postherpetic |
2010-11-25 |
2026-02-15 |
Treatments |
|
ACTRN12610000620022 |
ACTRN12610000620022 | P1 |
Completed |
Neuralgia, Postherpetic |
2010-10-21 |
2026-02-15 |
Treatments |
|
ACTRN12610000798066 |
ACTRN12610000798066 | P1 |
Completed |
Neuralgia, Postherpetic |
2010-10-12 |
2026-02-15 |
Treatments |
|
ACTRN12609000489291 |
ACTRN12609000489291 | P1 |
Completed |
Neuralgia, Postherpetic |
2009-09-25 |
2026-02-15 |
Treatments |
|
ACTRN12608000335392 |
ACTRN12608000335392 | P1 |
Completed |
Neuralgia, Postherpetic |
None |
2026-02-15 |
Treatments |
|
JapicCTI-173816 |
JapicCTI-173816 | P2 |
Terminated |
Neuralgia |
2020-08-28 |
|||
2016-000280-16 |
EMPHENE | P2 |
Completed |
Neuralgia |
2019-07-16 |
2022-03-13 |
Treatments |
|
NCT03297294 |
EMPADINE | P2 |
Terminated |
Peripheral Nervous System Diseases |
2019-03-25 |
50% |
2020-06-05 |
Primary Endpoints|Treatments|Trial Status |
2016-000281-39 |
EMPADINE | P2 |
Completed |
Pain Unspecified |
2019-03-25 |
50% |
2025-06-14 |
Treatments |
NCT03094195 |
EMPHENE | P2 |
Terminated |
Neuralgia, Postherpetic |
2019-03-07 |
50% |
2020-05-15 |
Primary Endpoints|Treatments|Trial Status |
NCT02426411 |
EMA401-006 | P2 |
Withdrawn |
Neuralgia, Postherpetic |
2016-10-01 |
2019-03-20 |
Treatments |
|
NCT02435199 |
EMA401-011 | P2 |
Withdrawn |
Pain Unspecified |
2016-10-01 |
2019-03-20 |
Treatments |
|
2011-004033-13 |
A study of EMA401 and biomarkers in the treatment of pain due to nerve damage following chemotherapy | P2 |
Completed |
Neuropathic Pain|Chemotherapy-induced Peripheral Neuropathy |
2014-07-21 |
2022-03-13 |
Treatments |
|
ACTRN12611001092987 |
ACTRN12611001092987 | P2 |
Completed |
Chemotherapy-induced Peripheral Neuropathy|Neuropathic Pain |
2014-01-30 |
2026-02-15 |
Treatments |
|
2011-000977-29 |
2011-000977-29 | P2 |
Completed |
Neuralgia, Postherpetic |
2012-07-11 |
2022-03-13 |
Treatments |
|
ACTRN12611000822987 |
ACTRN12611000822987 | P2 |
Completed |
Neuralgia, Postherpetic |
2012-05-18 |
2026-02-15 |
Treatments |